BMY Q4 2020 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q4 2020 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.1B+39.3% YoY

Gross Profit

$6.2B56.4% margin

Operating Income

$731M6.6% margin

Net Income

-$10.0B-90.6% margin

EPS (Diluted)

$-4.45

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$3.7B

Free Cash Flow

$3.4B

Stock-Based Comp.

$171M

Balance Sheet

Total Assets

$118.5B

Total Liabilities

$80.6B

Stockholders' Equity

$37.8B

Cash & Equivalents

$14.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.1B	$7.9B	+39.3%
Gross Profit	$6.2B	$4.4B	+41.3%
Operating Income	$731M	$701M	+4.3%
Net Income	-$10.0B	-$1.1B	-849.5%

Revenue Segments

Revlimid

$3.3B30%

Eliquis

$2.3B21%

Opdivo

$1.8B16%

Orencia

$867M8%

Pomalyst/Imnovid

$835M8%

Sprycel

$564M5%

Yervoy

$471M4%

Abraxane

$297M3%

Mature Products And All Other

$279M3%

Reblozyl

$115M1%

Baraclude

$104M1%

Empliciti

$91M1%

Zeposia

$9M0%

Geographic Segments

UNITED STATES

$6.8B61%

Europe

$2.7B24%

Rest Of World

$1.4B13%

Other Region

$162M1%